Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
about
Mechanisms of Autoantibody-Induced Pathology.FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII.Proteomic Analysis of Pemphigus Autoantibodies Indicates a Larger, More Diverse, and More Dynamic Repertoire than Determined by B Cell Genetics.Setting the target for pemphigus vulgaris therapy.Deep Proteome Profiling Reveals Common Prevalence of MZB1-positive Plasma B Cells in Human Lung and Skin Fibrosis.CAR T-Cell Therapy: Progress and Prospects.In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance.CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.The multiple pathways to autoimmunity.Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.Treatment of membranous nephropathy: time for a paradigm shift.Antigen-specific immunotherapies in rheumatic diseases.Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.Therapeutic T cell engineering.Like Angler Fish, CAARs Lure Their Prey.Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with PrecisionFrom IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.B cells in the pathophysiology of myasthenia gravis.High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.Rewiring T-cell responses to soluble factors with chimeric antigen receptors.Current Status of Gene Engineering Cell Therapeutics.New insights into pemphigoid diseases.Autoimmune diseases: CAR-T cells take aim at autoimmunity.Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs.The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy.Notable advances 2016.Gene Therapy With Regulatory T Cells: A Beneficial Alliance.Montagna Symposium 2017-Precision Dermatology: Next Generation Prevention, Diagnosis, and Treatment.New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.B Cell Modulation Strategies in Autoimmune Diseases: New Concepts.Humoral Epitope Spreading in Autoimmune Bullous Diseases.Emerging treatment options for the management of pemphigus vulgaris.PemphigusEngineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivoSurface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes
P2860
Q33740580-D06B2D3D-E067-43CD-9AC6-644871B60BCDQ36243815-9A55DD98-B787-4345-A5A1-C94C883751C8Q37573339-5508CA20-ED9B-4C8A-91E7-864D34C239FEQ37677416-E3652BC2-AB61-43A4-8B21-CFB164F982CCQ38666089-01B3FEBF-B031-4251-870B-B4D1E07BFAD6Q38741433-221A7997-34B6-483F-AF9E-FB5FD5DA61D0Q39245827-70727921-C0C1-49E6-9C5F-C14FA278F584Q39246685-8F11A17F-4086-4253-B97F-26081484C42DQ39264898-6BADDE46-5384-41ED-BF24-961385D42990Q39272183-FC02824B-78C0-41B5-B886-4760B7B7DD55Q39386100-BF5D2D6C-27F8-4E6E-B103-88B230CE81FFQ39398719-F74A9B09-303F-46B5-960F-FD82F6B3E88DQ39410091-07856732-BEA9-4A33-913A-02BA9F590D70Q39431371-5ECF4FE9-4982-49D7-B457-8298BF3D4EBCQ40064246-F6BD5C8E-21C3-4247-AECD-4527AAF37543Q40199809-E5518D23-4C37-41E4-94EB-713DA0209CD0Q41092986-8AC6BEC4-44D4-4FC8-9C01-2373AF8323A3Q42072531-6008793B-2E8B-4DE1-88CB-997AE6EBA3A5Q45875104-308AE155-61EF-44B2-B1C0-3C75133CD36EQ47219879-5EDC0CCF-1ABF-4CC8-9211-1D2024FD6E54Q47756482-D38BEC9C-667F-4EF7-BAE5-E71BB9C66D88Q47947865-2593D995-9D2A-4988-A4B0-AA9A9DD050A0Q48152533-659491D7-FD78-4E0E-9FBF-F742A66000BBQ49829282-E78D3D0C-2A0C-4236-9262-A1EDF36B90CBQ49842338-432444F5-D414-4B5E-9581-3E5E13DE0B76Q50040670-7154023C-9343-42D0-A044-67FE01CC5212Q52336320-BF9B68AA-A609-4268-8AD3-C98E22C11A89Q52349819-AD5431DC-8D1E-44BB-9D3D-6DBE8222BA31Q52426493-985EED57-F94A-407A-AAB3-C1937F01EAB3Q52721830-DDEA3671-2FE7-49E3-BCF6-FEC68FA892D1Q52725991-D88FF31D-E2FA-49C4-8907-194D559545A6Q53383480-C441CD3B-792B-431F-9034-DCCDD3C24C69Q54980047-3C79AFFC-06A7-4896-ABD8-45B827B7B776Q55262188-3DA4A4E4-63EF-41DF-81B1-95480EAAE4E4Q55433740-4614AFFF-5071-4D72-9875-F6E4B09F44B9Q56603745-97611213-5ADB-4B2E-9D5A-725F8CB6114DQ57150012-AA6A4C4B-9FF7-44BA-8CF4-71F4D3B5364AQ58726929-3A1267BB-1B88-49FD-BD56-373F9978D210
P2860
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Reengineering chimeric antigen ...... therapy of autoimmune disease
@ast
Reengineering chimeric antigen ...... therapy of autoimmune disease
@en
Reengineering chimeric antigen ...... therapy of autoimmune disease
@nl
type
label
Reengineering chimeric antigen ...... therapy of autoimmune disease
@ast
Reengineering chimeric antigen ...... therapy of autoimmune disease
@en
Reengineering chimeric antigen ...... therapy of autoimmune disease
@nl
prefLabel
Reengineering chimeric antigen ...... therapy of autoimmune disease
@ast
Reengineering chimeric antigen ...... therapy of autoimmune disease
@en
Reengineering chimeric antigen ...... therapy of autoimmune disease
@nl
P2093
P2860
P356
P1433
P1476
Reengineering chimeric antigen ...... therapy of autoimmune disease
@en
P2093
Aimee S Payne
Arben Nace
Christoph T Ellebrecht
Eun Jung Choi
George Cotsarelis
Giovanni Di Zenzo
John T Seykora
Michael C Milone
Michael Jeffrey Cho
Vijay G Bhoj
P2860
P304
P356
10.1126/SCIENCE.AAF6756
P407
P577
2016-07-08T00:00:00Z